Wells Fargo raised the firm’s price target on CVS Health to $61 from $60 and keeps an Equal Weight rating on the shares. Following Q2 results, the firm co-hosted a meeting with CVS management team. Unsurprisingly, nearly all focus was on struggles at Aetna, Wells says. While visibility remains low, earnings power could clearly be much higher in 2-3 years if company can execute well, the firm adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target lowered to $63 from $64 at Deutsche Bank
- CVS Health price target lowered to $62 from $65 at Evercore ISI
- CVS Health price target lowered to $63 from $65 at Barclays
- CVS Health price target raised to $62 from $58 at Cantor Fitzgerald
- Net Lease Office sells office property leased to CVS Health for $71.5M